196 related articles for article (PubMed ID: 19183192)
1. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
Lapalombella R; Gowda A; Joshi T; Mehter N; Cheney C; Lehman A; Chen CS; Johnson AJ; Caligiuri MA; Tridandapani S; Muthusamy N; Byrd JC
Br J Haematol; 2009 Mar; 144(6):848-55. PubMed ID: 19183192
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Tai YT; Li XF; Catley L; Coffey R; Breitkreutz I; Bae J; Song W; Podar K; Hideshima T; Chauhan D; Schlossman R; Richardson P; Treon SP; Grewal IS; Munshi NC; Anderson KC
Cancer Res; 2005 Dec; 65(24):11712-20. PubMed ID: 16357183
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
[TBL] [Abstract][Full Text] [Related]
4. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
Lapalombella R; Yu B; Triantafillou G; Liu Q; Butchar JP; Lozanski G; Ramanunni A; Smith LL; Blum W; Andritsos L; Wang DS; Lehman A; Chen CS; Johnson AJ; Marcucci G; Lee RJ; Lee LJ; Tridandapani S; Muthusamy N; Byrd JC
Blood; 2008 Dec; 112(13):5180-9. PubMed ID: 18772452
[TBL] [Abstract][Full Text] [Related]
6. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
Awan FT; Lapalombella R; Trotta R; Butchar JP; Yu B; Benson DM; Roda JM; Cheney C; Mo X; Lehman A; Jones J; Flynn J; Jarjoura D; Desjarlais JR; Tridandapani S; Caligiuri MA; Muthusamy N; Byrd JC
Blood; 2010 Feb; 115(6):1204-13. PubMed ID: 19965644
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
[TBL] [Abstract][Full Text] [Related]
9. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
Chanan-Khan AA; Chitta K; Ersing N; Paulus A; Masood A; Sher T; Swaika A; Wallace PK; Mashtare TL; Wilding G; Lee K; Czuczman MS; Borrello I; Bangia N
Br J Haematol; 2011 Nov; 155(4):457-67. PubMed ID: 22010965
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
Masood A; Chitta K; Paulus A; Khan AN; Sher T; Ersing N; Miller KC; Manfredi D; Ailawadhi S; Borrelo I; Lee KP; Chanan-Khan A
Br J Haematol; 2012 Apr; 157(1):59-66. PubMed ID: 22171982
[TBL] [Abstract][Full Text] [Related]
14. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.
Robak T
Curr Cancer Drug Targets; 2008 Mar; 8(2):156-71. PubMed ID: 18336199
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Winqvist M; Mozaffari F; Palma M; Eketorp Sylvan S; Hansson L; Mellstedt H; Österborg A; Lundin J
Cancer Immunol Immunother; 2017 Jan; 66(1):91-102. PubMed ID: 27815572
[TBL] [Abstract][Full Text] [Related]
16. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia.
Riches JC; Gribben JG
Semin Hematol; 2014 Jul; 51(3):228-34. PubMed ID: 25048786
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
Chen CI
Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
Browning RL; Byrd WH; Gupta N; Jones J; Mo X; Hertlein E; Yu L; Muthusamy N; Byrd JC
Cancer Immunol Res; 2016 Aug; 4(8):698-707. PubMed ID: 27287425
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide and chronic lymphocytic leukemia.
González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
